论文部分内容阅读
自1913年Eppinger首次用切脾来治疗再生障碍性贫血(再障)以来,目前国内外对其疗效评价不一。现将我院近年来切脾治疗再障50例进行分析如下: (一)病例选择男30例、女20例,年龄自15~53岁,其中30岁以下35例。起病至手术时间1年以上17例,6个月~1年10例,6个月以内23例。病史9个月以上,经内科治疗4个月以上无效者
Since Eppinger first used splenectomy in 1913 to treat aplastic anemia (aplastic anemia), the efficacy of Eppinger has not been evaluated at home and abroad. Now in our hospital in recent years, splenectomy treatment of aplastic anemia in 50 cases were analyzed as follows: (a) 30 cases of males and 20 females, aged 15 to 53 years, of which 35 were under the age of 30. From onset to operation more than 1 year in 17 cases, 6 months to 1 year in 10 cases, 6 months within 23 cases. A history of more than 9 months, medical treatment more than 4 months invalid